

## SELECTA BIOSCIENCES, INC.

### RESEARCH AND DEVELOPMENT COMMITTEE CHARTER

**Effective:** September 24, 2021

#### **A. Purpose**

The purpose of the Research and Development Committee (the “*Committee*”) of the Board of Directors (the “*Board*”) of Selecta Biosciences, Inc. (the “*Company*”) is to support, assist and advise the Board in its general duties of oversight of the Company’s technology, research and development efforts, including as it relates to the Company’s product pipeline and manufacturing thereof. The Committee will advise the Board on the strategic direction of the Company with respect to the Company’s product pipeline and technology, and provide advice on the scientific, technical, medical, or clinical implications of potential business development opportunities.

#### **B. Structure and Membership**

1. Number. The Committee shall consist of such number of directors and other advisors as the Board shall determine from time to time. The Committee shall be comprised of members determined by the Board to have appropriate scientific, medical, or other relevant expertise.
2. Chair. The Board shall appoint a Chair of the Committee.
3. Compensation. The compensation of Committee members shall be as determined by the Board.
4. Selection and Removal. Members of the Committee shall be appointed by the Board, upon the recommendation of the Nominating and Corporate Governance Committee. The Board may remove members of the Committee, at any time and with or without cause.

#### **C. Authority and Responsibilities**

The Committee shall be responsible for:

1. Reviewing the Company’s research and development strategy as well as the Company’s long-term strategic goals and objectives, and monitoring the Company’s progress in achieving such goals and objectives;
2. Advising the Board on scientific, technological, and research and development matters, and on strategic issues associated with the Company’s product pipeline and technology;

3. Reviewing and discussing the effectiveness and competitiveness of the Company's position and strategies in relation to emerging scientific and technology trends and activities relevant to the success of the Company's product pipeline and technology;
4. Reviewing the quality, direction, and competitiveness of the Company's research and development programs, and product pipeline;
5. Reviewing the organization, resources and capabilities of the Company's research, analytical, CMC, and clinical departments;
6. Reviewing strategies and approaches to acquiring, inlicensing, outlicensing, and maintaining innovation and technology positions;
7. Advising the Board on the scientific, medical, and technical aspects of significant acquisitions, inlicenses, outlicenses, and other strategic business development transactions;
8. Assisting the Company in reviewing, as requested, the capabilities of the Company's current and prospective key scientific, clinical, medical, or technical personnel and engagement with key opinion leaders, and the depth and breadth of the Company's scientific resources
9. Advising the Board, and the committees of the Board, as requested, with regard to performance and succession planning of the Company's officers and other leadership of the research and development, manufacturing, medical, and other technical or scientific functions within the Company;
10. Providing counsel and know-how to the Company's management in the area of research and development and the Company's product pipeline and technology;
11. Carrying out other tasks or providing other advice related to the Company's product pipeline and technology as may be requested by the Board; and
12. Periodically evaluating its own performance and report to the Board on that self-evaluation.

#### ADDITIONAL AUTHORITY

13. The Committee is authorized, without further action by the Board, to engage and rely on the advice of such independent scientific, medical, technical, and other advisors as it deems necessary or appropriate to carry out its responsibilities. Such independent advisors may be retained as regular observers of and advisors to the Committee, and also

may be regular advisors to the Company. The Committee is empowered, without further action by the Board, to cause the Company to pay the reasonable compensation of such advisors as established by the Committee.

14. The Committee is authorized, without further action by the Board, to engage such independent legal and other advisors as it deems necessary or appropriate to carry out its responsibilities. Such independent advisors may be regular advisors to the Company. The Committee is empowered, without further action by the Board, to cause the Company to pay the reasonable compensation of such advisors as established by the Committee.
15. The Committee is empowered, without further action by the Board, to cause the Company to pay the ordinary administrative expenses of the Committee that are necessary or appropriate in carrying out its duties.
16. To enable the Committee to perform its duties, the Committee or any individual members of the Committee may request and hold separate meetings with any employees or consultants of the Company.

#### **D. Procedures and Administration**

1. Meetings. The Committee shall meet as often as it deems necessary in order to perform its responsibilities. The Committee may also act by unanimous written consent in lieu of a meeting. The Committee shall keep minutes of its meetings as it shall deem appropriate and report the same to the Board upon request. The Committee shall also periodically meet separately with the Company's key scientific, clinical, medical, or technical personnel
2. Subcommittees. The Committee may form and delegate any of its responsibility to subcommittees as it deems necessary or appropriate in its sole discretion.
3. Quorum. The quorum of the meeting is a majority of its members. Decisions are made by simple majority vote.
4. Reports to Board. The Committee shall report regularly to the Board, and, when requested or where appropriate, shall present recommendations to the Board of Directors.
5. Charter. The Committee shall periodically review and reassess the adequacy of this Charter and recommend any proposed changes to the Board for approval.